Sentences with phrase «based biopharmaceutical company»

For Leslie Dunlop, vice president and corporate counsel at Bioniche Life Sciences Inc., a publicly traded, Belleville, Ont. - based biopharmaceutical company that «discovers, develops, manufactures, and markets proprietary products for human and animal health markets,» a constant issue for her and her company is adhering to the many regulatory requirements of securities law, including the obligation to disclose material information in a timely way.

Sinovac Biotech, Ltd. is a fully integrated, profitable China - based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

Since the initial Michigan trial, the liposomal transport system — developed by researchers at Vical, a San Diego - based biopharmaceutical company interested in gene therapy — has been altered in ways that are expected to make it safer, more effective and easier to administer.

So Waseem Qasim at University College London created UCART19 cells with help from Paris - based biopharmaceutical company Cellectis instead.

In Texas the Ebola patient is now stable but in critical condition and being treated with brincidofovir, an oral medicine developed by Durham, N.C. — based biopharmaceutical company, Chimerix.

AbbVie is a global, research - based biopharmaceutical company formed in 2013 following separation from Abbott.

AbbVie is a new global, research - based biopharmaceutical company that combines the focus and passion of a leading - edge biotech, with the expertise and results of a long - established pharmaceutical leader.

Shire is a Dublin - based biopharmaceutical company that researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products.

The Colorado - based biopharmaceutical company owns the worldwide rights to the drug.

• Lundbeck agreed to acquire Prexton Therapeutics, a Netherlands - based biopharmaceutical company, for 100 million euros ($ 123 million) and will later pay up to 805 million euros ($ 989 million) in development and sales milestones.

To this end, Calico has also forged a partnership with a Chicago - based biopharmaceutical company called AbbVie, in order to develop drugs that will tackle aging and age - related diseases such as neurodegeneration and cancer.

• Outpost Medicine, an Indianapolis and London - based biopharmaceutical company focused on treating urologic and gastrointestinal disorders, raised $ 20 million in funding.

• Zai Lab Limited, a Shanghai - based biopharmaceutical company, raised $ 30 million in Series C funding.

• Tessa Therapeutics, a Singapore - based biopharmaceutical company focusing on T cell therapy for solid tumors, raised $ 80 million in funding.

• FLX Bio Inc, a South San Francisco - based biopharmaceutical company focused on activating the immune system against cancer, raised $ 60 million in Series C funding.

• Vicarius Pharma AG, a Switzerland - based which provides U.S. - based biopharmaceutical companies a new approach to commercializing assets in European markets, raised $ 21.8 million in funding.

Not exact matches

• BridgeBio Pharma, a Palo Alto, Calif. - based clinical - stage biopharmaceutical company, raised $ 135 million in funding.

• UroGen Pharma, an Israel - based clinical stage biopharmaceutical company, announced terms for its IPO.

• Clementia Pharmaceuticals, a Montreal, Canada - based clinical stage biopharmaceutical company focused on bone diseases, filed for an IPO to raise $ 115 million.

Acceleron is a Cambridge - based, clinical - stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

Google - backed biotech company Calico has also forged a partnership with a Chicago - based biopharmaceutical firm to develop age - defying drugs.

• Arsanis, a Waltham, Mass. - based clinical stage biopharmaceutical company focused on monoclonal antibodies, raised $ 40 million in an offering of 4 million shares at $ 10 a piece, below its $ 15 to $ 17 range.

• Aptinyx Inc., an Evanston, Ill. - based clinical - stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, raised $ 70 million in Series B funding.

Durect, Corp., a biopharmaceutical company developing therapeutics based on its epigenetic regulator program and proprietary drug delivery platforms, posted an all - time low of 61 cents in November 2012 before embarking on an uptrend that topped out at $ 3.42 in June 2015.

DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development: New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator program.

Macrogenics, a biopharmaceutical company, is focused on discovering and developing innovative antibody - based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

In April 2011, TransMolecular's tumour - targeter was snapped up by biopharmaceutical company Morphotek, a US - based subsidiary of Japanese drug giant Eisai.

This year, almost 7,000 answered the web - based questionnaire; 94 % were employed in a biotech, biopharmaceutical, or pharmaceutical company.

PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche.

Vyriad is a clinical stage, biopharmaceutical company based in Rochester, Minn., that specializes in the development of powerful oncolytic virus therapies, using engineered viruses designed to selectively and rapidly destroy cancer.

Bristol - Myers Squibb Company is a global biopharmaceutical Company, which is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis.

Paraktek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.

SAN DIEGO and ALAMEDA, Calif., June 25, 2009 (GLOBE NEWSWIRE)-- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq: MNOV — News) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), and Avigen, Inc. (Nasdaq: AVGN — News), a biopharmaceutical company, today announced that they have confirmed their understanding of certain key terms for a proposed acquisition of Avigen by MediciNova that would combine the companies» broad neurological clinical development programs based on ibudilast (Avigen's AV - 411 and MediciNova's MN - 166).

VXGN is a biopharmaceutical company based in South San Francisco, California.